Mankind Pharma Sees Sharp Open Interest Surge Amid Bullish Derivatives Activity

Open Interest and Volume Dynamics

The latest data reveals that Mankind Pharma’s open interest (OI) in derivatives rose sharply by 2,144 contracts, an 11.59% increase from the previous figure of 18,491 to 20,635. This uptick in OI coincided with a robust volume of 31,275 contracts traded, indicating heightened trader activity and fresh positions being established rather than merely offsetting existing ones.

In monetary terms, the futures segment alone accounted for a value of approximately ₹28,353 lakhs, while the options segment reflected a substantial ₹13,241 crore in value, culminating in a total derivatives value of ₹31,146 lakhs. This level of liquidity underscores the stock’s attractiveness for active trading and strategic positioning.

Price Performance and Market Context

On the price front, Mankind Pharma outperformed the Pharmaceuticals & Biotechnology sector by 1.6% on the day, registering a 3.06% gain compared to the sector’s 1.38% and the Sensex’s 0.88%. The stock touched an intraday high of ₹2,244.5, marking a 3.75% rise, and reversed its recent two-day downward trend. Notably, the stock price remains above its 5-day, 20-day, 50-day, and 100-day moving averages, though it is still trading below the 200-day moving average, suggesting a medium-term resistance level yet to be breached.

Investor participation is also on the rise, with delivery volumes reaching 3.36 lakh shares on 9 Mar 2026, a 1.35% increase over the five-day average delivery volume. This indicates growing conviction among investors to hold the stock rather than engage in short-term trading.

Market Positioning and Directional Bets

The surge in open interest alongside rising volumes and price appreciation points to a constructive shift in market positioning. Traders appear to be taking fresh long positions, anticipating further upside potential in Mankind Pharma. The increase in OI by over 11% is significant in the context of the stock’s ₹90,652 crore market capitalisation, reflecting renewed interest from both institutional and retail participants.

Given the stock’s current mojo score of 44.0 and a recent downgrade from Hold to Sell on 19 Nov 2025, this spike in derivatives activity may indicate a divergence between short-term market sentiment and longer-term fundamental assessments. The market seems to be pricing in a potential recovery or positive catalyst that could drive the stock higher in the near term.

Technical Indicators and Moving Averages

The stock’s position relative to its moving averages provides further insight into its technical health. Trading above the short- and medium-term averages (5, 20, 50, and 100 days) suggests a positive momentum build-up, while the resistance posed by the 200-day moving average remains a key hurdle. A sustained breakout above this level could confirm a longer-term uptrend and attract additional buying interest.

Liquidity metrics also support active trading, with the stock’s average traded value allowing for sizeable trade sizes up to ₹2.46 crore without significant market impact. This liquidity is crucial for institutional investors and large traders looking to establish or unwind positions efficiently.

Sector and Market Comparison

Within the Pharmaceuticals & Biotechnology sector, Mankind Pharma’s outperformance on the day is notable. The sector’s 1.38% gain was overshadowed by the stock’s 3.06% rise, highlighting its relative strength. Compared to the broader Sensex’s 0.88% increase, the stock’s performance underscores its appeal amid sectoral and market-wide movements.

However, the company’s mojo grade remains at Sell with a score of 44.0, reflecting underlying concerns or valuation pressures that may temper enthusiasm. Investors should weigh these factors carefully against the recent surge in derivatives activity and price momentum.

Implications for Investors

The recent surge in open interest and volume in Mankind Pharma’s derivatives market suggests that traders are positioning for a potential upward move. This could be driven by expectations of favourable earnings, regulatory developments, or sectoral tailwinds. However, the existing mojo grade downgrade and the stock’s position below the 200-day moving average counsel caution.

Investors should monitor whether the stock can sustain its momentum and break through key resistance levels. Additionally, tracking changes in open interest alongside price movements will be critical to discerning whether the market’s directional bets are confirmed or reversed.

Given the stock’s mid-cap status and ₹90,652 crore market capitalisation, it remains a significant player within the Pharmaceuticals & Biotechnology sector, offering both opportunities and risks for investors seeking exposure to this space.

Conclusion

Mankind Pharma Ltd’s derivatives market activity has intensified, with an 11.59% rise in open interest and strong volume supporting a 3.15% price gain. This reflects growing investor interest and a possible shift in market sentiment towards a more bullish stance. While technical indicators and liquidity conditions are favourable, the stock’s mojo grade downgrade and resistance at the 200-day moving average suggest that investors should remain vigilant and consider both fundamental and technical factors before committing capital.

Overall, the surge in open interest is a key signal of increased market participation and directional bets, making Mankind Pharma a stock to watch closely in the coming sessions.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →